UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.267

Sortiert nach

Dendrogenin A drives LXR to trigger lethal autophagy in cancers

Nature communications, 2017-12, Vol.8 (1), p.1903-17, Article 1903

2017

Volltextzugriff (PDF)

Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients

International journal of molecular sciences, 2023-09, Vol.24 (18), p.14348

2023

Volltextzugriff (PDF)

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients

British journal of clinical pharmacology, 2019-06, Vol.85 (6), p.1357-1366

2019

Volltextzugriff (PDF)

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study

Pharmaceuticals (Basel, Switzerland), 2021-08, Vol.14 (8), p.796

2021

Volltextzugriff (PDF)

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

Fundamental & clinical pharmacology, 2015-06, Vol.29 (3), p.219-237

2015

Volltextzugriff (PDF)

Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr

CPT: pharmacometrics and systems pharmacology, 2021-10, Vol.10 (10), p.1208-1220

2021

Volltextzugriff (PDF)

Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients

Clinical pharmacokinetics, 2016-09, Vol.55 (9), p.1145-1157

2016

Volltextzugriff (PDF)

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

European journal of cancer (1990), 2009-09, Vol.45 (13), p.2316-2323

2009

Volltextzugriff (PDF)

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data

Pharmaceuticals (Basel, Switzerland), 2021-02, Vol.14 (2), p.162

2021

Volltextzugriff (PDF)

Reply to the letter addressed by Amr A. EL-Arabey “Dual function of OCT-2 and MATE1 in Cisplatin induced nephrotoxicity”

Pharmacological research, 2017-05, Vol.119, p.494-494

Thomas, Fabienne

2017

Volltextzugriff (PDF)

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site

Investigational new drugs, 2016-02, Vol.34 (1), p.41-48

2016

Volltextzugriff (PDF)

Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma

Journal of clinical oncology, 2011-03, Vol.29 (7), p.875-883

2011

Volltextzugriff (PDF)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury

Metabolites, 2022-09, Vol.12 (9), p.852

2022

Volltextzugriff (PDF)

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Cancer medicine (Malden, MA), 2021-04, Vol.10 (7), p.2250-2258

2021

Volltextzugriff (PDF)

Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children

Clinical cancer research, 2011-07, Vol.17 (14), p.4862-4871

2011

Volltextzugriff (PDF)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma

Cancers, 2020-12, Vol.12 (12), p.3647

2020

Volltextzugriff (PDF)

Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2007-12, Vol.13 (23), p.7086-7092

2007

Volltextzugriff (PDF)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

Journal of personalized medicine, 2021-08, Vol.11 (8), p.792

2021

Volltextzugriff (PDF)

Pharmacogenetics of anti-cancer drugs: State of the art and implementation – recommendations of the French National Network of Pharmacogenetics

Therapie, 2017-04, Vol.72 (2), p.205-215

2017

Volltextzugriff (PDF)

Increased Tissue Diffusion of Oxaliplatin During Laparoscopically Assisted Versus Open Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC)

Annals of surgical oncology, 2008-12, Vol.15 (12), p.3623-3624

2008

Volltextzugriff (PDF)

Pharmacogenomics: the influence of genomic variation on drug response

Current topics in medicinal chemistry, 2004-01, Vol.4 (13), p.1399

2004

Volltextzugriff (PDF)

Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer

Cancer research (Chicago, Ill.), 2021-12, Vol.81 (23), p.5963-5976

2021

Volltextzugriff (PDF)

Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer

Cancer research (Chicago, Ill.), 2022-04, Vol.82 (7), p.1436-1436

2022

Volltextzugriff (PDF)

Pharmacogénétique des médicaments anticancéreux : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx)

Therapie, 2017-04, Vol.72 (2), p.193-204

2017

Volltextzugriff (PDF)

1 – 25 von 1.267

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.142)
Mit Volltextzugriff
(1.164)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Dendrogenin A drives LXR to trigger lethal autophagy in cancers

New advances in DPYD genotype and risk of severe toxicity under capecitabine

Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr

Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data

Reply to the letter addressed by Amr A. EL-Arabey “Dual function of OCT-2 and MATE1 in Cisplatin induced nephrotoxicity”

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site

Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma

Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

Pharmacogenetics of anti-cancer drugs: State of the art and implementation – recommendations of the French National Network of Pharmacogenetics

Increased Tissue Diffusion of Oxaliplatin During Laparoscopically Assisted Versus Open Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC)

Pharmacogenomics: the influence of genomic variation on drug response

Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer

Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer

Pharmacogénétique des médicaments anticancéreux : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx)

Suchergebnisse filtern